Status:
COMPLETED
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This phase I/II trial is studying the side effects and best dose of belinostat and to see how well it works in treating patients with liver cancer that cannot be removed by surgery. Belinostat may sto...
Detailed Description
PRIMARY OBJECTIVES: I. Determine the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD) of PXD101 (belinostat) in patients with unresectable hepatocellular carcinoma (HCC). (...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically or cytologically confirmed hepatocellular carcinoma that is not amenable to curative resection
- Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques OR as ≥ 10 mm with MRI or spiral CT scan
- No known brain metastases
- No clinical ascites or encephalopathy
- Life expectancy \> 12 weeks
- ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
- WBC ≥ 3,000/mm³
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ 1.7 mg/dL
- Albumin ≥ 2.8 mg/dL
- ALT ≤ 5.0 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 6 times ULN
- Prothrombin time ≤ 4 sec above ULN
- Creatinine ≤ 1.6 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients use effective contraception
- No Child's-Pugh's grading Class C hepatic impairment
- No history of allergic reaction attributed to compounds of similar chemical or biologic composition to PXD101
- No marked baseline prolongation of QT/QTc interval, including the following:
- Repeated demonstration of a QTc interval \> 500 msec
- Long QT Syndrome
- No ongoing or active infection
- No significant cardiovascular disease, including any of the following:
- Unstable angina pectoris
- Uncontrolled hypertension
- Congestive heart failure related to primary cardiac disease
- Condition requiring anti-arrhythmic therapy
- Ischemic or severe valvular heart disease
- Myocardial infarction within the past 6 months
- No psychiatric illness or social situation that would preclude study compliance
- No other uncontrolled illness
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered
- More than 4 weeks since prior radiotherapy and recovered
- At least 2 weeks since prior valproic acid
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No concurrent participation in another investigational study
- No other concurrent investigational agents
- No other concurrent anticancer therapy
- No concurrent use of any of the following:
- Disopyramide
- Dofetilide
- Ibutilide
- Procainamide
- Quinidine
- Sotalol
- Bepridil
- Amiodarone
- Arsenic trioxide
- Cisapride
- Calcium channel blockers (e.g., lidoflazine)
- Clarithromycin
- Erythromycin
- Halofantrine
- Pentamidine
- Sparfloxacin
- Domperidone
- Droperidol
- Chlorpromazine
- Haloperidol
- Mesoridazine
- Thioridazine
- Pimozide
- Methadone
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00321594
Start Date
May 1 2006
End Date
October 1 2012
Last Update
November 6 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
2
Cancer Therapeutics Research Group
Singapore, Singapore, 119074